DHR

Danaher Corporation

• Seeking Alpha·1d ago

  Dividend Champion, Contender, And Challenger Highlights: Week Of April 19

• Dow Jones·1d ago

  Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

• Dow Jones·1d ago

  Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

• Simply Wall St·1d ago

  Will Danaher’s (DHR) Push Into Rapid Infectious Disease Diagnostics Reshape Its Risk‑Reward Narrative?

• TipRanks·1d ago

  Danaher Establishes New $5 Billion Revolving Credit Facility

• Dow Jones·1d ago

  Danaher Is Maintained at Outperform by Baird

• Dow Jones·1d ago

  Danaher Price Target Cut to $249.00/Share From $251.00 by Baird

• Benzinga·1d ago

  Baird Maintains Outperform on Danaher, Lowers Price Target to $249

• TipRanks·1d ago

  Danaher price target lowered to $249 from $251 at Baird

• TipRanks·1d ago

  Danaher price target lowered to $205 from $220 at Rothschild & Co Redburn

• TipRanks·2d ago

  Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Annexon Biosciences (ANNX) and UnitedHealth (UNH)

• Seeking Alpha·3d ago

  Mar Vista U.S. Quality Premier adds Ecolab, GE Vernova, QXO, exits Salesforce, SAP

• Seeking Alpha·3d ago

  Mar Vista U.S. Quality Premier Portfolio: Q1 2026 Leaders And Laggards

• Simply Wall St·4d ago

  Assessing Danaher (DHR) Valuation After New Access MeMed BV Diagnostic Approval

• Dow Jones·4d ago

  Danaher Price Target Cut to $230.00/Share From $250.00 by Barclays